Beneficial effects of atorvastatin in the treatment of hyperlipidemia after renal transplantation

Despite the availability of various lipid lowering drugs, the treatment of hyperlipidemia, one of the most important risk factors for morbidity and mo rtality after organ transplantation, remains a therapeutic challenge. We in vestigated the safety and efficacy of a new HMG-CoA reductase inhibitor, at orvastatin, in renal transplant patients whose serum lipids were insufficie ntly controlled by diet and treatment with other lipid lowering drugs. Twen ty-four patients (14 males/10 females; mean age 51.2 +/- 2.3 years) were co nverted to low dose atorvastatin (10 mg/day) at a mean of 67.7 +/- 8.6 mont hs after renal transplantation and prospectively followed for 3 months afte r initiation of the study drug. HDL, LDL, and total cholesterol, triglyceri des, serum creatinine and CPK levels were evaluated pre (-3, -1, 0 months) and post conversion (+1, +3 months). in the eighteen patients who completed the study, low dose atorvastatin therapy led to a significant reduction in total cholesterol (304.6 +/- 13.2 vs. 247.6 +/- 12.0 mg/dl; p = 0.007) and LDL cholesterol (191.9 +/- 9.0 vs. 141.8 +/- 14.7 mg/dl; p < 0.0001) and a modest reduction in serum triglyceride levels at three months after conver sion. We conclude that low dose atorvastatin (10 mg/day) can be successfully used and appears to be safe in the treatment of posttransplant hyperlipidemia. Its long-term effects on patient morbidity and mortality as well as graft s urvival should be investigated in larger and more prolonged prospective tri als.